Interfering with the ERα pathway using anti-oestrogens (selective oestrogen receptor modulators such as tamoxifen or selective oestrogen down-regulators such as fulvestrant) or oestrogen deprivation (e.g., aromatase inhibitors), increases the survival of ERα-positive BC patients. Here, CYP19A1 is linked to breast cancer.